Pfizer Sues J&J Over ‘Exclusionary Contracts’ to Block Biosimilar Infliximab

Drug Industry Daily
A A
Pfizer is suing Johnson & Johnson over its contracts and rebate policies with insurers and hospitals, saying they are designed to block sales of a biosimilar for J&J’s blockbuster Remicade therapy.

To View This Article:

Login

Subscribe To Drug Industry Daily